
    
      The activity of feasibility of the proposed program will be assessed in HIV+ patients with
      Burkitt lymphoma with the aim to improve tolerability, minimize source consuming and
      supporting treatment and redu ce late sequels. Available combinations in this setting are
      really source demanding and toxic combinations showing high rates of septic complication and
      a treatment-related mortality of near 20%.
    
  